Science & Technology
Science and TechnologyScience and Technology 
Fri, February 18, 2011
Thu, February 17, 2011
Synteract Achieves Rave Accreditation in Medidataa?s ASPire to Win Channel Program
SAN DIEGO--([ BUSINESS WIRE ])--[ Synteract ], Inc., a full-service, global contract research organization (CRO) dedicated to meeting the clinical research needs of biotechnology, medical device, and pharmaceutical companies, has achieved Rave Accredited status in the Medidata Solutions (NASDAQ: MDSO) [ ASPire to Win ]® channel partner program. With this accreditation, Synteract has increased its [ Medidata Rave ]® expertise to be able to offer in-house database development and other services to provide superior customer service as well as faster timelines and reduced costs for clients.
"As we continue to expand internationally, Medidata Ravea™s flexibility, scalable performance and broad EDC and CDM capabilities, including enhanced capabilities for site monitoring and safety reporting, will enable us to better support all sizes of studies and customers in their clinical research operations, both internationally and domestically."
The Medidata ASPire to Win accreditation enables Synteract to provide sponsors with [ comprehensive study support ]a" including full study build, data management, technical staff training, administration and reporting services a" using Medidata Rave, a leading electronic data capture (EDC) and clinical data management (CDM) solution. Comprised of a series of training and support levels from Rave Aware to Rave Ready to Rave Accredited, Medidataa™s ASPire to Win program enables partners at each level to gain additional skills and increased marketing support from Medidata. Having achieved all three previous levels, Synteract has embarked on the highest level of training, Rave Accredited Plus, expected to be completed in Q2, 2011.
aRave accreditation continues our goal of ever-increasing the value of customer support we provide our sponsors,a said Ellen Morgan, president and CEO of Synteract. aAs we continue to expand internationally, Medidata Ravea™s flexibility, scalable performance and broad EDC and CDM capabilities, including enhanced capabilities for site monitoring and safety reporting, will enable us to better support all sizes of studies and customers in their clinical research operations, both internationally and domestically.a
Synteract, which prides itself on being a aCRO with Charactera focusing on responsiveness and integrity, has a great [ repeat business track record ] (greater than 90 percent) due to the quality of its work and strong customer service. Synteract has offices on both East and West coasts of the United States, and operations in the Czech Republic as well as [ alliances ] with CROs in multiple geographic locations. The company viewed Medidata Ravea™s broad market acceptance, with usage at investigator sites in over 100 countries, and its extensive multilingual support as important criteria in selecting Rave as the system to support its continued global growth.
aSynteract has responded to the growing global demand for Medidata Rave, and, after joining the ASPire to Win program in June of last year, moved quickly through the accreditation process in order to provide its customers with comprehensive Medidata Rave-related services,a said Graham Bunn, vice president for Global CRO Partnerships, Medidata Solutions. aAs a leading CRO with diverse expertise, Synteract will continue to broaden its clinical trial capabilities as it moves towards Rave Accredited Plus.a
About Medidata Solutions Worldwide
Medidata Solutions ([ www.mdsol.com ]) is a leading global provider of SaaS-based clinical development solutions that enhance the efficiency of customersa™ clinical trials. For over 10 years, Medidata has consistently brought next-generation innovation to the life science industry to lower the total cost of clinical development through informed trial planning and management, optimized clinical processes and platform interoperability.
About Synteract
[ Synteract ] is a privately-held, full-service contract research organization, serving clinical trial needs of biotechnology, medical device, and pharmaceutical companies. Synteract provides high quality, customized service, working closely with drug and device sponsors. Headquartered in California, with offices in North Carolina and Czech Republic, Synteract offers clinical expertise in multiple therapeutic areas, including a strong emphasis in oncology, central nervous system (CNS), cardiovascular, respiratory, and ophthalmology. Information: [ http://www.synteract.com ]; (760) 268.8200.